Y Toyonaga

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Nationwide survey of the development of drug resistance in the pediatric field in 2000–2001, 2004, 2007, 2010, and 2012: Evaluation of the changes in drug sensitivity of Haemophilus influenzae and patients' background factors

Hiroyuki Shiro, Yoshitake Sato, Y Toyonaga et al. · Journal of Infection and Chemotherapy · 2014 · 43 citations

Medicine, Infectious Diseases, Pediatrics +15

Nationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in Japan

Hiroshi Sakata, Y Toyonaga, Yoshitake Sato et al. · Journal of Infection and Chemotherapy · 2009 · 26 citations

Medicine, Infectious Diseases, Pediatrics +15

Nationwide survey of the development of drug resistance in the pediatric field in 2007 and 2010: drug sensitivity of Haemophilus influenzae in Japan (second report)

Tadashi Hoshino, Yoshitake Sato, Y Toyonaga et al. · Journal of Infection and Chemotherapy · 2013 · 24 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17